Well, we don’t know the specifics of the test evidence sets used by UK and German regulators. These will be specific to each regulatory regime and the way that they are interpreted and the decision criteria/risk tolerability used in each case will differ (and will take into account local norms and legal basis). Personally, I have confidence in our regulator on this matter, if they are concluding that rollout is deemed sufficiently ‘safe’, (taking into account the health benefit gained vs. residual risk and bearing in mind that nothing is 100% ‘safe’).